Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

RNAi and high-content screening in target identification and validation.

Steven A Haney1

  • 1Wyeth Research, Section of Applied Genomics, Department of Biological Technologies, Cambridge, MA 02140, USA. shaney@wyeth.com

Idrugs : the Investigational Drugs Journal
|December 2, 2005
PubMed
Summary

RNA interference (RNAi) combined with high-content screening (HCS) offers a powerful approach for validating therapeutic targets. This integrated method overcomes challenges, providing unique advantages for drug discovery programs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peak emission wavelength and fluorescence lifetime are coupled in far-red, GFP-like fluorescent proteins.

PloS one·2018
Same author

Perspective: SBI<sup>2</sup> at Its Fifth Annual Meeting.

Assay and drug development technologies·2018
Same author

High-Content Screening Approaches That Minimize Confounding Factors in RNAi, CRISPR, and Small Molecule Screening.

Methods in molecular biology (Clifton, N.J.)·2017
Same author

Biologically Relevant Heterogeneity: Metrics and Practical Insights.

SLAS discovery : advancing life sciences R & D·2017
Same author

Rapid Assessment and Visualization of Normality in High-Content and Other Cell-Level Data and Its Impact on the Interpretation of Experimental Results.

Journal of biomolecular screening·2014
Same author

Interview with Steven A. Haney, PhD.

Assay and drug development technologies·2014

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Drug Discovery

Background:

  • Developing novel therapeutic agents is challenging, requiring validation of critical disease targets.
  • RNA interference (RNAi) is a scalable technology essential for studying disease models.
  • High-content screening (HCS) quantitatively measures cellular features, offering superior signal transduction analysis over reporter assays.

Purpose of the Study:

  • To highlight the convergence of RNAi and HCS for target validation.
  • To discuss the advantages and challenges of integrating these technologies.

Main Methods:

  • Utilizing RNA interference (RNAi) for target knockdown.
  • Employing high-content screening (HCS) for quantitative cellular analysis.
  • Integrating RNAi screening into HCS platforms.

Related Experiment Videos

Main Results:

  • HCS provides robust, image-based data, minimizing assay artifacts.
  • Statistical tools associated with HCS enhance data interpretation.
  • Combining RNAi and HCS presents unique benefits for target validation.

Conclusions:

  • The integration of RNAi and HCS is crucial for effective target validation.
  • This combined approach offers significant advantages for therapeutic agent development.
  • Overcoming integration challenges unlocks powerful insights for disease research.